Trial · NCT00977938
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT | 18 months (12-30 months post-index procedure) | All randomized DES ITT patients; Patients were analyzed according to the treatment to which they were randomized (regardless of post-randomization compliance with the randomized treatment); Patients not experiencing the endpoint were censored at 30 months or at last known follow-up, whichever was earlier. | percentage of patients (KM estimate) | NUMBER |
| PRIMARY | Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT | 18 months (12-30 months post-index procedure) | All randomized DES ITT patients; Patients were analyzed according to the treatment to which they were randomized (regardless of post-randomization compliance with the randomized treatment); Patients not experiencing the endpoint were censored at 30 months or at last known follow-up, whichever was earlier. | percentage of patients (KM estimate) | NUMBER |
| PRIMARY | GUSTO Severe or Moderate Bleeding - Randomized DES ITT | 18 months (12-30 months post-index procedure) | Only patients who could be evaluated were included in this analysis (i.e., patients whose last contact date was ≥510 days after randomization or who had any adjudicated bleeding event at or before 540 days). | percentage of patients | NUMBER |
| SECONDARY | MACCE (Death, Myocardial Infarction or Stroke) - Propensity Matched DES vs. BMS | 33 months (0-33 months post-index procedure) | A subsample created by matching BMS- to DES-treated patients exactly on prevalence of STEMI and then matching on remaining baseline characteristics via propensity score, using a caliper width of 0.10. A BMS-treated patient was matched to a variable number of DES-treated patients without replacement, up to a maximum of 8. | percentage of patients | NUMBER |
| SECONDARY | Definite or Probable Stent Thrombosis (ST) - Propensity Matched DES vs. BMS | 33 months (0-33 months post-index procedure) | A subsample created by matching BMS- to DES-treated patients exactly on prevalence of STEMI and then matching on remaining baseline characteristics via propensity score, using a caliper width of 0.10. A BMS-treated patient was matched to a variable number of DES-treated patients without replacement, up to a maximum of 8. | percentage of patients | NUMBER |
| SECONDARY | MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT | 21 months (12-33 months post-index procedure) | All randomized DES ITT patients; Patients were analyzed according to the treatment to which they were randomized (regardless of post-randomization compliance with the randomized treatment); Patients not experiencing the endpoint were censored at 33 months or at last known follow-up, whichever was earlier. | percentage of patients (KM estimate) | NUMBER |
| SECONDARY | Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT | 21 months (12-33 months post-index procedure) | All randomized DES ITT patients; Patients were analyzed according to the treatment to which they were randomized (regardless of post-randomization compliance with the randomized treatment); Patients not experiencing the endpoint were censored at 33 months or at last known follow-up, whichever was earlier. | percentage of patients (KM estimate) | NUMBER |
| SECONDARY | GUSTO Severe or Moderate Bleeding - Randomized DES ITT | 21 months (12-33 months post-index procedure) | Only patients who could be evaluated were included in this analysis (i.e., patients whose last contact date was ≥600 days after randomization or who had any adjudicated bleeding event at or before 630 days). | percentage of patients | NUMBER |
| SECONDARY | MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT | 18 months (12-30 months post-index procedure) | All randomized BMS ITT patients; Patients were analyzed according to the treatment to which they were randomized (regardless of post-randomization compliance with the randomized treatment); Patients not experiencing the endpoint were censored at 30 months or at last known follow-up, whichever was earlier. | percentage of patients (KM estimate) | NUMBER |
| SECONDARY | Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT | 18 months (12-30 months post-index procedure) | All randomized BMS ITT patients; Patients were analyzed according to the treatment to which they were randomized (regardless of post-randomization compliance with the randomized treatment); Patients not experiencing the endpoint were censored at 30 months or at last known follow-up, whichever was earlier. | percentage of patients (KM estimate) | NUMBER |
| SECONDARY | GUSTO Severe or Moderate Bleeding - Randomized BMS ITT | 18 months (12-30 months post-index procedure) | Only patients who could be evaluated were included in this analysis (i.e., patients whose last contact date was ≥510 days after randomization or who had any adjudicated bleeding event at or before 540 days). | percentage of patients | NUMBER |
| SECONDARY | MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT | 21 months (12-33 months post-index procedure) | All randomized BMS ITT patients; Patients were analyzed according to the treatment to which they were randomized (regardless of post-randomization compliance with the randomized treatment); Patients not experiencing the endpoint were censored at 33 months or at last known follow-up, whichever was earlier. | percentage of patients (KM estimate) | NUMBER |
| SECONDARY | Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT | 21 months (12-33 months post-index procedure) | All randomized BMS ITT patients; Patients were analyzed according to the treatment to which they were randomized (regardless of post-randomization compliance with the randomized treatment); Patients not experiencing the endpoint were censored at 33 months or at last known follow-up, whichever was earlier. | percentage of patients (KM estimate) | NUMBER |
| SECONDARY | GUSTO Severe or Moderate Bleeding - Randomized BMS ITT | 21 months (12-33 months post-index procedure) | Only patients who could be evaluated were included in this analysis (i.e., patients whose last contact date was ≥600 days after randomization or who had any adjudicated bleeding event at or before 630 days). | percentage of patients | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00977938/outcomes